KRAS and neoplasm: In our study, we observed that patients with the KRAS G12C mutation exhibited significantly poorer survival compared to other patient groups suggesting a more aggressive disease and/or difficulty to treat the tumor with complex mutational landscape, at least without effective targeted therapies.